CWK

NEW YORK--(BUSINESS WIRE)-- #cre--The U.S. life sciences real estate sector is moving toward a gradual rebalancing as development activity contracts, investment sales recover and funding conditions strengthen, according to the latest Life Sciences Update from Cushman & Wakefield. While elevated vacancy and softer rents continue to weigh on near-term fundamentals, a reduced construction pipeline and improving demand indicators are positioning the market for healthier long-term growth. U.S. life sci.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

HOUSTON--(BUSINESS WIRE)-- #CRE--Cushman & Wakefield announced today that Drew Morris has joined the firm as Executive Managing Director. Morris joins Cushman & Wakefield's Houston office tenant representation group, which has a long history of providing market-leading advisory services for clients locally, nationally and globally. For his part, Morris brings nearly 30 years of commercial real estate experience to his new role, where he will continue to specialize in creating and implementing.

Cushman & Wakefield remains a Buy as fundamentals strengthen and FY2026 adj. EPS growth guidance is raised to 18%-23%. Leasing and Services drive near-term growth, with Americas leasing up 35% and Services pipeline visibility extending 12 months. Data center exposure is a significant catalyst, with data-center-related revenue up 83% YTD and comprising 25% of CWK's IFM pipeline.

Evaluate Cushman & Wakefield's (CWK) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Cushman & Wakefield NYSE: CWK reported record second-quarter revenue and raised its full-year adjusted earnings outlook, citing broad-based leasing strength, continued services growth and progress reducing debt.

The average of price targets set by Wall Street analysts indicates a potential upside of 25.7% in Cushman & Wakefield (CWK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Although the revenue and EPS for Cushman & Wakefield (CWK) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Cushman & Wakefield (CWK) came out with quarterly earnings of $0.35 per share, missing the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.3 per share a year ago.

Cushman & Wakefield (CWK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.